Figure 1.
Inhibition of ID8-T Tumor Growth and Accumulation of sCXCR4-A in Peritoneal Washes of Tumor-Bearing Mice, Sera, and Lymphoid Organs after i.v. or i.p. Delivery of OVV-CXCR4-A and sCXCR4-A
(A and B) C57BL/6 female mice (n = 5–10 mice/group) were challenged i.p. with 3 × 105 ID8-T tumor cells and treated with sCXCR4-A (10 μg/injection for 7 days), OVV or OVV-CXCR4-A (108 PFU), or OVV and sCXCR4 combinations injected i.v. (A) or i.p. (B) 10 days after tumor challenge. Control mice were treated with RPMI-1640 medium. Tumor progression was monitored by bioluminescence. Kaplan-Meier survival plots were prepared, and significance was determined using the log rank method. *p < 0.05, **p < 0.01, ***p < 0.001. (C and D) Accumulation of sCXCR4-A in peritoneal washes, sera, and lymphoid organs of tumor-bearing mice after i.v. or i.p. delivery of OVV-CXCR4-A (C) or sCXCR4-A (D) to ID8-T tumor-bearing mice. Concentrations of sCXCR4-A in sera, peritoneal washes (denoted as tumors), livers, BM, lymph nodes, and spleens were determined on day 8 after treatment by ELISA after normalization to total protein content. Data are presented as the mean ± SD of five mice per group. **p < 0.01, ***p < 0.001.